英语阅读双语新闻

时事新闻:试验性爱滋病疫苗取得进展

本文已影响 5.36K人 

【英文原文】

时事新闻:试验性爱滋病疫苗取得进展

Experimental HIV Vaccine Gives Some Protection
An experimental vaccine regimen has shown a modest ability to protect people exposed to HIV, the first time an investigational HIV vaccine has been shown to have this effect.

The results from the trial, which involved more than 16,000 adults in Thailand, indicated that the vaccine regimen lowered the rate of contracting HIV by 31% compared with those taking a placebo, according to the U.S. National Institutes of Health, which helped fund the study.

'Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field,' said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is part of the NIH.

It is a rare piece of good news for the field of AIDS vaccine research, which has sponsored more than 100 vaccine trials since 1987 but without any significant success.

The regimen consists of two vaccines. One is a primer dose made by Sanofi Pasteur, the vaccine division of French drug maker Sanofi-Aventis; the other is a booster dose developed by Vaxgen Inc. and now licensed to Global Solutions for Infectious Diseases, in South San Francisco, Calif.



【中文译文】

一种试验性免疫疫苗疗法显示出可适当保护爱滋病病毒(HIV)易感人群,这是尚在研究阶段的HIV疫苗首次显示出有此效果。

赞助这项研究的美国国立卫生研究院(U.S. National Institutes of Health)的资料显示,针对泰国逾1.6万名成人的试验结果显示,与服用安慰剂的对照组相比,采用这种免疫疫苗疗法的HIV感染率下降了31%。

国立卫生研究院下属的国家过敏症与传染病研究所(National Institute of Allergy and Infectious Diseases)所长法奇(Anthony Fauci)说,还需要进一步研究,以便更好地了解这种免疫法降低HIV感染风险的机制,但这肯定是HIV疫苗领域的一个鼓舞人心的进展。

这是爱滋病疫苗领域极为罕见的好消息,该领域自1987年以来已赞助了100多项疫苗试验,但没有任何重大成就。

这一免疫法由两种疫苗组成。其一是法国药品制造商赛诺菲安万特(Sanofi-Aventis)旗下生产疫苗的子公司Sanofi Pasteur生产的基础疫苗;另一种是Vaxgen Inc.开发的加强剂,现已授权给位于加州旧金山市的非赢利组织传染性疾病全球解决方案(Global Solutions for Infectious Diseases)。

猜你喜欢

热点阅读

最新文章